focus -WSS

focus

author：Wikipedia 2025-09-29 18:17:29 - browse：88215

Fran van Delft for Galapagos

Seeking to differentiate itself from other makers of CAR-T cancer therapies, Galapagos NV on Wednesday announced it had struck a deal with Blood Centers of America to open up dozens of manufacturing sites for its cell-based medicines around the U.S.

Galapagos said it will rely on the partnership, the financial terms of which were not disclosed, as it moves its CAR-Ts for different cancers into pivotal studies and could also help launch those medicines should they win approval. The Belgian company framed the collaboration as one that could help overcome the limitations that have held back access to existing CAR-T therapies from other companies.

CAR-Ts have proven to be potent treatments for certain cancers, but they are complicated medicines to make. Immune cells have to be removed from a patient, shipped to specialty sites, where they’re engineered with cancer-killing abilities, and then returned to the hospital for infusion back into patients. The process, which can take weeks if not months, has put a crunch on the number of patients companies and hospitals are able to treat.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Biogen joins immunology wave with $1.15 billion acquisition of HI

WSS

Digital health: a case of mistaken identity

Change Healthcare outage fallout shows need for new oversight

How many hemophilia patients actually want gene therapy?

Pushing for an NIH office for post

Citing H5N1 threat, CDC urges peak flu monitoring this summer

Readout Newsletter: CAR

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Heart attack and stroke risk calculators need revising

Addressing health care workers' trauma can help fight burnout

Peter Hotez and the public health issue of online harassment

FDA advisers back CAR

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Bird flu surveillance in wastewater gets boost from consortium

Medical leaders decry Supreme Court decision on affirmative action

President Biden's budget: Here's what you might have missed

knowledge

FDA advisers back CAR

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Liver decline slowed by off

Biogen joins immunology wave with $1.15 billion acquisition of HI

UCLA team creates talking throat patch for voice disorders

HHS secretary Becerra pressed on Change HealthCare cyberattack

hotspot

Wikipedia

focus

leisure time